Foundayo and Type 2 Diabetes : How the Dual Licence Works in the UK

Foundayo and Type 2 Diabetes: How the Dual Licence Works

Foundayo® (orforglipron) is best known as a weight-management tablet, but its UK authorisation actually covers two separate uses: weight management, and improving blood sugar control in adults with type 2 diabetes. This dual licence is genuinely significant, and the evidence behind the diabetes indication is strong — in head-to-head trial data, Foundayo has outperformed oral semaglutide, one of the most established oral diabetes treatments available. This guide explains what the dual licence actually means, what the evidence shows, and how eligibility for the diabetes indication differs from the weight-management one.

Quick Answer

Foundayo was authorised by the MHRA on 10 August 2026 for both weight management and for improving blood sugar control in adults with type 2 diabetes, based on Lilly's ACHIEVE clinical trial programme. In the head-to-head ACHIEVE-3 trial, Foundayo at 9mg reduced HbA1c by an average of 1.9 percentage points, and at 17.2mg by 2.2 percentage points, both outperforming equivalent doses of oral semaglutide (1.1% and 1.4% respectively). These are two genuinely separate clinical indications — eligibility for one doesn't automatically confirm eligibility for the other, and your prescriber will assess which applies to your specific circumstances.

2 licensed usesweight management and improving blood sugar control in type 2 diabetes, under one UK authorisation

Up to 2.2%average HbA1c reduction at Foundayo's highest dose in the ACHIEVE-3 head-to-head trial

4 trialsACHIEVE-1, 2, 3 and 5 make up the core diabetes evidence programme

What the Dual Licence Actually Means

Many GLP-1 medicines are licensed for only one of these two uses — for example, Wegovy is licensed for weight management, while some other GLP-1 medicines are licensed only for diabetes. Foundayo is one of a small number of medicines authorised in the UK for both, reflecting a genuinely strong evidence base in each population. This matters practically: if you have type 2 diabetes and are also managing your weight, Foundayo's diabetes indication is based on its own dedicated trial programme (ACHIEVE), separate from the weight-management evidence (ATTAIN) covered in our other Foundayo guides.

The ACHIEVE Trial Programme: What the Evidence Shows

ACHIEVE-1: Foundayo vs Placebo

This 40-week trial in adults with early type 2 diabetes tested three doses of orforglipron as a standalone treatment against placebo. All doses significantly reduced HbA1c compared with placebo, with the highest dose achieving a 1.48 percentage point reduction from baseline. The trial also showed dose-dependent weight loss and improvements in fasting glucose, triglycerides and cholesterol, with mild-to-moderate gastrointestinal side effects and no severe hypoglycaemia reported.

ACHIEVE-3: The Head-to-Head Trial Against Oral Semaglutide

This is the standout result in the programme — the first and only head-to-head Phase 3 trial comparing two oral GLP-1 medicines for type 2 diabetes. Foundayo at 9mg and 17.2mg outperformed oral semaglutide at 7mg and 14mg across the primary and all key secondary endpoints.

Dose comparison	HbA1c reduction
Foundayo 9mg vs oral semaglutide 7mg	1.9% vs 1.1%
Foundayo 17.2mg vs oral semaglutide 14mg	2.2% vs 1.4%

Foundayo's highest dose also produced 73.6% greater relative weight loss compared with the equivalent oral semaglutide dose in this trial.

ACHIEVE-2: Foundayo vs Dapagliflozin (Farxiga)

In this trial, Foundayo was compared against dapagliflozin, an SGLT2 inhibitor and another commonly used oral diabetes medicine. Foundayo reduced HbA1c by an average of 1.7 percentage points at 40 weeks, compared with 0.8 percentage points with dapagliflozin — more than double the effect.

ACHIEVE-5: Foundayo Added to Insulin

This trial studied Foundayo added on top of existing insulin glargine treatment, relevant for people with more advanced type 2 diabetes already using insulin. Foundayo achieved up to a 2.1 percentage point average HbA1c reduction at 40 weeks, compared with 0.8 percentage points for placebo added to insulin.

Worth knowing

Across ACHIEVE-2 and ACHIEVE-5, up to 68.6% and 69.1% of participants respectively reached an HbA1c goal of 6.5% or below — a commonly used clinical target for good diabetes control. This is a meaningful proportion of people reaching a genuinely strong outcome, not just a modest average improvement.

How Eligibility Differs Between the Two Indications

It's important to understand that meeting the criteria for one Foundayo indication doesn't automatically mean you're eligible for the other.

	Weight management indication	Type 2 diabetes indication
Core criteria	BMI 30+, or 27–30 with a weight-related condition	Insufficiently controlled type 2 diabetes, alongside diet and exercise
Primary goal	Weight loss and maintenance	Improved blood sugar (HbA1c) control
Evidence base	ATTAIN trial programme	ACHIEVE trial programme

Someone with type 2 diabetes and a BMI below the weight-management threshold could still be eligible for Foundayo under the diabetes indication alone, and vice versa. Your prescriber will consider which licensed use genuinely applies to your circumstances during your consultation — see our dedicated eligibility guide for the full breakdown of exclusions and cautions that apply across both indications.

Dosing: Is It Different for Diabetes?

The ACHIEVE trials studied a range of doses, including some (like 3mg and 36mg) that differ from Foundayo's approved weight-management titration schedule. Your prescriber will determine the appropriate starting dose and titration pace for your specific indication and circumstances — see our dedicated dosage and titration guide for the standard approved schedule.

Important

If you're taking Foundayo for type 2 diabetes alongside insulin or a sulfonylurea, your risk of hypoglycaemia is higher than with Foundayo alone, since these medicines lower blood sugar regardless of your current level. Your prescriber may need to adjust your other diabetes medicines when starting Foundayo, and you should be familiar with the signs and symptoms of low blood sugar before beginning treatment.

Side Effects: Similar, With a Notable Difference in Trial Discontinuation

Gastrointestinal side effects — nausea, diarrhoea, vomiting — are the most commonly reported across the ACHIEVE trials, consistent with Foundayo's weight-management side-effect profile covered in our dedicated side effects guide. One detail worth being transparent about: discontinuation rates due to side effects were somewhat higher with Foundayo than with the comparator treatments in these trials — for example, 8.7% and 9.7% for Foundayo's two doses in ACHIEVE-3, compared with 4.5% and 4.9% for oral semaglutide. This reflects the genuine trade-off of a highly effective medicine with a meaningful GI side-effect profile, and is worth discussing openly with your prescriber, who can help pace your titration to minimise discomfort.

Why This Matters Beyond the Numbers

Type 2 diabetes and excess weight are closely linked conditions, and a medicine effective at treating both through one daily tablet offers a genuinely simplified treatment approach for many people managing both simultaneously — rather than needing entirely separate medicines and monitoring pathways for each. The strength of the head-to-head data against oral semaglutide, one of the most widely prescribed oral diabetes treatments, is also a meaningful marker of where oral GLP-1 treatment for diabetes may be heading more broadly across UK clinical practice in the coming years.

How This Fits Alongside Other Diabetes Treatments

Metformin remains the standard first-line treatment for type 2 diabetes in the UK, and Foundayo isn't intended to replace this as a starting point for most people. The ACHIEVE trials generally studied Foundayo either as an early addition for people not adequately controlled on existing treatment, or in more advanced cases already using insulin. Your prescriber will consider where Foundayo fits within your existing diabetes management plan, rather than treating it as an automatic first choice for everyone with type 2 diabetes.

Frequently Asked Questions

Is Foundayo licensed for type 2 diabetes in the UK?

Yes. Foundayo's UK authorisation, granted by the MHRA on 10 August 2026, covers both weight management and improving blood sugar control in adults with type 2 diabetes.

Does Foundayo work better than other diabetes tablets?

In head-to-head trial data (ACHIEVE-3), Foundayo produced greater HbA1c reductions than oral semaglutide, and in ACHIEVE-2, greater reductions than dapagliflozin. These are strong results, though individual response always varies.

Can I take Foundayo for diabetes if I don't need to lose weight?

Potentially, yes — the diabetes indication is a separate clinical pathway from the weight-management one, based on its own trial evidence. Eligibility depends on your specific diabetes control and circumstances, assessed by your prescriber.

What is HbA1c and why does it matter?

HbA1c is a blood test measuring average blood sugar levels over the past two to three months, widely used to assess diabetes control. A commonly used clinical target is 6.5% or below, though individual targets can vary.

Is the dosing different for diabetes versus weight management?

The approved UK titration schedule follows the same general structure, but your prescriber will determine the specific approach appropriate to your indication and circumstances.

Can I take Foundayo alongside insulin?

This was studied in the ACHIEVE-5 trial, which found Foundayo added to insulin produced meaningful additional HbA1c reduction. However, this combination increases hypoglycaemia risk and needs careful management by your prescriber.

How does Foundayo compare to Farxiga (dapagliflozin) for diabetes?

In the ACHIEVE-2 trial, Foundayo produced more than double the average HbA1c reduction compared with dapagliflozin at 40 weeks.

Will Foundayo also help me lose weight if I'm taking it for diabetes?

Weight loss was a secondary outcome across the ACHIEVE trials and was consistently observed, though the primary goal of the diabetes indication is blood sugar control rather than weight loss specifically.

Do I need a different consultation for the diabetes indication versus weight management?

Your consultation will cover your full medical history and current condition, allowing your prescriber to determine which indication applies and whether Foundayo is appropriate for your specific situation.

Is Foundayo available for diabetes treatment in the UK?

Yes. Foundayo was authorised by the MHRA on 10 August 2026 for both indications and is available to order now through Happy Pharmacy.

Does Foundayo replace metformin?

No. Metformin remains the standard first-line treatment for type 2 diabetes, and Foundayo is generally considered as an addition when existing treatment isn't providing adequate control, or in more advanced cases, rather than a first-choice replacement.

Where were the ACHIEVE trial results published?

ACHIEVE-1 was published in the New England Journal of Medicine, while ACHIEVE-2 and ACHIEVE-3 were published in The Lancet and presented at the American Diabetes Association's 86th Scientific Sessions.

Manage Your Weight and Blood Sugar With Foundayo®

Foundayo® is available to order now through Happy Pharmacy, licensed for both weight management and improving blood sugar control in type 2 diabetes. A free online consultation with our GPhC-registered pharmacy team will confirm which indication applies to you.

Start Your Free Online Consultation → Happy Pharmacy is a GPhC-registered pharmacy (No. 9012585) — Superintendent Pharmacist: Palvinder Deol — Rated 4.8★ Excellent on Trustpilot

MHRA. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes, 10 August 2026.
Rosenstock J, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1). N Engl J Med. 2025.
Rosenstock J, et al. ACHIEVE-2 and ACHIEVE-3: Foundayo vs dapagliflozin and oral semaglutide in type 2 diabetes. Lancet. 2026.
Eli Lilly and Company. Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials. Press release, June 2026.
Foundayo® (orforglipron) Summary of Product Characteristics, MHRA Products website.